Comparison of the Efficacy of ShuoTong Ureteroscopy and Simple Flexible Ureteroscopy in the Treatment of Unilateral Upper Ureteral Calculi.
Longhui Lai, Wenzhao Zhang, Fangjian Zheng...
https://pubmed.ncbi.nlm.nih.gov/34646858Actively Recruiting
Phase Not Applicable
Age: 18Years - 85Years
All Genders
Healthy Volunteers
ID05712785
Clinical Study on the Treatment of Upper Urinary Tract Stones Using Shuotong Ureteroscopy
Led by Handan First Hospital · Updated on 2023-03-16
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new device called the Shuotong ureteroscopy for treating patients with upper urinary tract stones. This study compares the Shuotong ureteroscopy, which can crush and remove stones simultaneously, with conventional ureteroscopy. The goal is to improve the rate at which stones are completely removed from the body and reduce complications like stone fragments remaining or blocking the ureter again. The study has two groups: patients treated with the Shuotong ureteroscopy device and those treated with conventional ureteroscopy methods. The Shuotong device allows surgeons to break and remove stones at the same time during a minimally invasive procedure through the natural urinary tract. This approach aims to be simpler, safer, and less traumatic, especially for larger stones in the upper urinary tract. Participants will undergo surgery and be monitored during the procedure for surgery time. One week after surgery, researchers will evaluate how effectively the stones were removed. Patients will be assessed for safety and stone removal success. The study started in 2020 and will continue until 2026. Participants between 18 and 85 years old with ureteral stones may take part in this trial.
CONDITIONS
Brief Title
Shuotongo Ureteroscopy for Upper Urinary Tract Stones
Who Can Participate
Age: 18Years - 85Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of ureteral calculus
- Must be able to cooperate with the treatment
- Age between 18 and 85 years
You will not qualify if you...
- Severe urinary tract infections
- Other medical conditions deemed unsuitable for the study by investigators
- Age outside 18 to 85 years range if applicable by screening criteria (implied by age limits but not explicitly stated in exclusion criteria)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Implementation
Duration - 1 day (surgery day)
Participants receive treatment using the Shuotong ureteroscopy device to remove ureteral stones with simultaneous stone crushing and removal.
1 surgery visit (in-person)
Post-operative Follow-up
Duration - 1 week
Participants are monitored after surgery to assess stone removal and recovery.
1 follow-up visit (in-person)
Trial Site Locations
Total: 1 location
1
Kunwu Yan
Handan, Hebei, China, 056000
Actively Recruiting
Loading map...
Research Team
K
kunwu yan, Master
X
xiaofei tian, Master
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Effect of ultra-mini percutaneous nephrolithotomy and ShuoTong ureteroscopy on the stress response, inflammatory indices, and urokinase level in patients with polycystic kidney disease complicated with renal calculus.
Du Qiao, Luo Cheng, Tian Xiaomei...
https://pubmed.ncbi.nlm.nih.gov/35818238Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis.
Shu Gan, Zhenlang Guo, Qianming Zou...
https://pubmed.ncbi.nlm.nih.gov/32539255